Po23-771 Effect of Fluvastatin Slow Release on the Structure of Erythrocyte Membrane in Patients With Hyperlipidemia

Broncel, Marlena; Cieślak, D.; Koter−Michalak, Maria; Duchnowicz, Piotr; Chojnowska-Jezierska, J

doi:10.1016/s1567-5688(07)71781-6

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cholesterol content of membranes is one of determining factors of membrane fluidity. Higher concentrations of membrane cholesterol and lower Na-K ATPase activity are observed in RBCs of patients with hyperlipidemia, and pravastatin reverses or lessens this condition independent of its cholesterol-lowering effect [39]. In the present study, the statin decreased plasma total cholesterol and increased Na-K ATPase activity, which agreed with these results.…”

Section: Discussionsupporting

confidence: 91%

Effect of coenzyme Q10 andArdisia japonicaBlume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs

et al. 2012

View full text Add to dashboard Cite

Forty guinea pigs were divided into four groups and fed 0.04% cholesterol based control diet, plus 0.05% simvastatin, and statin plus 0.1% CoQ10 or 10% Ardisia Japonica Blume (AJB) leave powder for 4 weeks. Plasma total cholesterol levels decreased significantly in all groups fed the statin-containing diet compared with that in guinea pigs fed the control diet (P < 0.01). Plasma and liver triglycerides decreased significantly in the statin plus CoQ10 group compared with those in the control (both P < 0.05). Maximum platelet aggregation was significantly higher in the statin plus CoQ10 group than that in the other groups (P < 0.05). Na-K ATPase activity increased in the statin group and decreased in the statin plus CoQ10 group (P < 0.01). Na-K co-transport and Na passive transport decreased significantly in the control group compared with those in the other groups (both P < 0.05). Intracellular Na was highest in the statin group and lowest in the statin plus CoQ10 group and was correlated with Na-K ATPase activity. Thiobarbituric acid reactive substance production in platelet-rich plasma and liver tended to decrease in the statin plus CoQ10 group compared with those in the other groups. Plasma glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase increased significantly in the statin group compared with those in the control (P < 0.05). These result suggest that antioxidant rich AJB did not have positive effects on cardiovascular disease parameters. The statin plus CoQ10 seemed to decrease cholesterol more efficiently than that of statin alone.

show abstract

Section: Discussionsupporting

confidence: 91%

Effect of coenzyme Q10 andArdisia japonicaBlume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Our previous studies on patients with type II hypercholesterolemia reveal decreases in membrane cholesterol concentration after only 4 weeks of treatment with atorvastatin [13], and after 8 weeks of treatment with atorvastatin or simvastatin [14]. Reduced cholesterol concentrations are also reported in other studies on statins.…”

Section: Discussionmentioning

confidence: 63%

The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study

Jackowska¹,

Pytel²,

Koter−Michalak³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

“…Флувастатин вызывал повышение активности СОД, ГЛП и каталазы в эритроцитах пациентов со стенокардией и смешанной формой гиперлипидемии [23]. В эритроцитах пациентов с нарушенным липидным обменом активность СОД, ГЛП и каталазы повышалась после 4 недель ежедневного приема аторвастатина или симвастатина и восстанавливалась к норме через 12 недель, тогда как правастатин повышал только активность каталазы и только после 12 недель терапии и не изменял активность СОД и ГЛП [5]. Таким образом, в вышеуказанных исследованиях описано четкое повышение активности СОД, ГЛП и каталазы в эритроцитах пациентов с разными болезнями при терапии статинами.…”

Section: рисунок1unclassified

“…Результатом окислительного повреждения мембранных белков и липидов является снижение текучести клеточной мембраны эритроцита [4]. Выявлено антиокислительное действие ингибиторов 3-гидрокси-3-метилглутарил-CoA-редуктазы (КФ 1.1.1.88) (статинов), не зависящее от их гипохолестеринемического влияния [5]. У пациентов с гипертонией, принимающих ингибитор ангиотензин-превращающего фермента (АПФ, КФ 3.4.15.1), кровяное давление понижается, а их комбинации со статинами понижают давление в ещё большей степени [6], что свидетельствует о синергичном действии двух типов лекарственных препаратов.…”

unclassified

Antioxidant enzymes in erythrocytes from hypertension patients receiving lisinopril monotherapy or combined lisinopril plus simvastatin therapy

Kosenko

Av²,

et al. 2011

BIOMED KHIM

View full text Add to dashboard Cite

Statins and angiotensin-converting enzyme (ACE) inhibitors have beneficial impact on the serum cholesterol and blood pressure. It is supposed that statins and ACE inhibitors may modify the antioxidative status of erythrocytes. The study objective was to compare the effects of two treatments, lisinopril alone vs lisinopril plus simvastatin, on erythrocyte antioxidant enzyme activities. The study involved 32 patients with arterial hypertension, the initial serum total cholesterol, LDL-cholesterol and triglycerides within the normal range. Patients of two groups, each of 16 subjects, were treated with lisinopril (10 mg/day) or with lisinopril (10 mg/day) plus simvastatin (20 mg/day). Before and after 3 and 6 months of follow-up therapy, activities of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GLR) in purified erythrocytes were determined. In all patients, significantly higher catalase activity (by 79.3-106.5%, p<0.0001) and significantly lower GPx activity (by 20.7-30.6%, p<0.001) were observed after therapy as compared to the baselines. Just the same results were obtained in both groups (lisinopril and lisinopril + simvastatin), after both periods (3 and 6 month) of treatments. SOD activity was increased only in the lisinopril group and only after 6 months (p=0.0345). No changes of GLR reductase activity were seen under all conditions indicated. Thus, the lisinopril monotherapy and combined lisinopril plus simvastatin therapy exhibit specific, pronounced and equipotent effects on antioxidant enzymes in human erythrocytes. Administration of lisinopril or lisinopril plus simvastatin may protect erythrocytes and other tissues from oxidative damage.

show abstract

Po23-771 Effect of Fluvastatin Slow Release on the Structure of Erythrocyte Membrane in Patients With Hyperlipidemia

Cited by 7 publications

References 0 publications

Effect of coenzyme Q10 andArdisia japonicaBlume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs

Effect of coenzyme Q10 andArdisia japonicaBlume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs

The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study

Antioxidant enzymes in erythrocytes from hypertension patients receiving lisinopril monotherapy or combined lisinopril plus simvastatin therapy

Contact Info

Product

Resources

About